期刊文献+

重组人干扰素β1a的纯化及其理化性质 被引量:1

Purification and physico-chemical property of recombinant human interferon β1a
原文传递
导出
摘要 目的纯化重组人干扰素β1a(recombinant human interferonβ1a,rhIFNβ1a),并分析其理化性质。方法应用15 L生物反应器悬浮微载体培养表达rhIFNβ1a的重组CHO细胞,细胞培养收获液经超滤浓缩、蓝胶亲和层析、脱盐和CM离子交换层析纯化后,采用水泡性口炎病毒抑制法测定rhIFNβ1a的效价;Lowry法测定蛋白含量;等电聚焦电泳法测定其等电点;SDS-PAGE和高效液相色谱法测定其纯度;Western blot法分析其免疫活性;SDS-PAGE和质谱仪测定其相对分子质量;圆二色谱法分析其二级结构。结果共纯化了3批样品,纯化的rhIFNβ1a平均蛋白浓度为0.284 0 mg/ml,平均比活可达1.06×108IU/mg,纯度达95%以上,蛋白质平均回收率为58.36%,蛋白质相对分子质量为20 445.0,等电点约为6.6,免疫活性良好,二级结构与国家标准品基本一致。结论成功纯化了rhIFNβ1a,并检测了其理化性质,为建立大规模制备rhIFNβ1a的生产工艺和制造检定规程,实现产业化奠定了基础。 Objective To purify recombinant human interferon β1a(rhIFNβ1a)and analyze its physico-chemical property.Methods Recombinant CHO cells for expression of rhIFNβ1a were cultured on suspended micro-carriers in a 15 L bioreactor,of which the harvest liquid was concentrated by ultrafiltration and purified by Blue Sepharose 6 Fast Flow,Sephadex G-25 and CM ion exchange chromatography,then determined for rhIFNβ1a titer by vesicular stomatitis virus(VSV)inhibition test,for protein content by Lowry method,for isoelectric point by isoelectric focusing electrophoresis,for purity by SDS-PAGE and HPLC,for immunological activity by Western blot,for relative molecular mass by SDSPAGE and mass spectrometry,and for secondary structure by circular dichroism spectrum.Results Three batches of rhIFN-β1a samples were purified,of which the mean protein content was 0.284 0 mg/ml,the mean specific activity was 1.06 × 108 IU/mg,the purity was more than 95%,the mean recovery of protein was 58.36%,the relative molecular mass was 20 445.0,the isoelectric point was about 6.6,the immunological activity was high,and the secondary structure was basically consistent with that of national standard.Conclusion The rhIFNβ1a was successfully purified,and its physic-chemical property was determined,which laid a foundation of development of requirement for large-scale preparation,control test and industrialization of rhIFNβ1a.
出处 《中国生物制品学杂志》 CAS CSCD 2013年第6期834-839,共6页 Chinese Journal of Biologicals
基金 广东省教育部产学研结合项目(2012B091100408) 深圳科技创新委2012年国际合作项目(ZYA201106100083A) 深圳科信局深科(JSA200903201200A)
关键词 中国仓鼠卵巢细胞 重组人干扰素β1a 纯化 生物活性 Chinese hamster ovary(CHO)cells Recombinant human interferon β1a(rhIFN β1a) Purification Biological activity
  • 相关文献

参考文献10

  • 1Borden EC,Sen GC,Uze G,et al.Interferons at age 50:past,current and future impact on biomedicine[J].Nat Rev DrugDiscov,2007,6(12):975-990.
  • 2银晓,关平原.干扰素的研究进展[J].畜牧与饲料科学,2008,29(2):65-68. 被引量:15
  • 3Runkel L,Meier W,Pepinsky RB,et al.Structural and fun-ctional differences between glycosylated and non-glycosylatedforms of human Interferon-β(IFN-β)[J].Pharm Res,1998,15(4):641-649.
  • 4Lundkvist M,Greiner E,Hillert J,et al.Multiple sclerosispatients lacking oligoclonal bands in the cerebrospinal fluid areless likely to develop neutralizing antibodies against interferonbeta[J].Mult Scler,2010,16(7):796-800.
  • 5Bekisz J,Schmeisser H,Hernandez J,et al.Human interferonsalpha,beta and omega[J].Growth Factors,2004,22(4):243-251.
  • 6谢琰臣,张华,许贤豪.干扰素-β治疗多发性硬化[J].中国神经免疫学和神经病学杂志,2006,13(2):124-127. 被引量:10
  • 7刘长暖,张翊,饶春明,林建伟,高凯,张明芳,王军志.重组人干扰素-β制品的质量标准研究[J].中国肿瘤生物治疗杂志,2000,7(3):212-215. 被引量:8
  • 8Kopperschlager,Bohme HJ,Hofmann E.Cibacron blue F3G-Aand related dyes as ligands in affinity chromatography[J].AdvBiochem Engi,1982,25(1):101-138.
  • 9Jonasch E,Haluska FG.Interferon in oncological practice:review of interferon biology,clinical applications,and toxicities[J].Oncologist,2001,6(1):34-55.
  • 10黄汉昌,姜招峰,朱宏吉.紫外圆二色光谱预测蛋白质结构的研究方法[J].化学通报,2007,70(7):501-506. 被引量:44

二级参考文献80

  • 1刘新垣.干扰素研究及其重大突破性研究进展[J].中国处方药,2004,3(7):33-35. 被引量:13
  • 2付加雷,宋长征.干扰素-τ的研究进展[J].药物生物技术,2006,13(1):74-78. 被引量:8
  • 3沈琼,黄滨,邵嘉亮,彭权,马林,古练权.运用圆二色谱研究酶与化合物相互作用的机理[J].中山大学学报(自然科学版),2006,45(4):62-64. 被引量:30
  • 4张彩,田志刚.γ干扰素的负向免疫调节作用[J].现代免疫学,2007,27(2):89-92. 被引量:17
  • 5[1]Vilcek.J.Novel interferons[J].Nat Immunol,2003,4(1):8-9.
  • 6[5]Kra-Badu G A,Aggrey S E.Identification of candidate genes at quantitative trait loci on chicken chromosome Z using orthologous comparison of chicken,mouse,and human genomes[J].In Silieo Biol,2005,(5-6):593-604.
  • 7[6]Mylisa R P,Eric T H.The Bordetel la bronchiseptica type III secretion system inhibits gamma interferon productiont hat is required for efficient antibody mediated bacterial clearance[J].Infection and Immunity,2006,74(2):1043-1049.
  • 8[8]Jason M Z,Gregory B L,Michael D R,et al.STATl-dependent and STATl-independent gene expression in murine immune cells following stimulation with interfer on-alpha[J].Cancer Immunol Immunother,2007,56:1845-1852.
  • 9[11]Cooksley W G,Piratvisuth T Leesd,et al.Peginterferon alpha-2a(40kDa):an advance in the treatment of hepatitis Beantigen-positive chronichep-atitis B[J].J Viml Hepat,2003,10(4):2981.
  • 10[12]Christian Bogdan.The function of type I interferon in an timierobial immunity[J].Cureent Opinion in Immunology,2000,12:419-424.

共引文献72

同被引文献26

  • 1曾国华,陈贻锴,J.shevitz.抗人A血型杂交瘤细胞高密度培养条件的研究[J].中国生物制品学杂志,1991,4(2):75-77. 被引量:1
  • 2Ribatti D. From the discovery d monoclonal antibodies to their thetic application: an historical reappraisal [ J ]. Immunol Lett, 2014, 161(1) : 96 -99.
  • 3Rastogi A, Tan SH, Banerjee S, et al. ERG monoclonal antibody in the diagnosis andbiological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity [ J ]. Monoclon Antib Immunodiagn Immunother, 2014, 33(4): 201 -208.
  • 4Li X, Iida M, Tada M, et al. Development of an anti-elaudin-3 and -4 bispeeifie monoclonal antibody for cancer diagnosis and therapy [J]. J Phannacol Exp Ther, 2014, 351(1) : 206 -213.
  • 5Pamnani R. Irmmmophenotyping of acute leukaemias by flow cytometry: a review[J]. East Aft: Med J, 2009, 86(12 Suppl) : $89 -$92.
  • 6Kato Y, Kaneko MK. A cce-specitlc rzonoclonal anfib(x reccgniz the aberrantly glycesylated podoplanin[J/OL]. Sci Rep, 2014, 4: 5924.
  • 7Liu JK. The history of monoclonal antibody development-Progress, remaining challenges and future innovations [ J ]. Ann Med Surg (Lond), 2014, 3(4) : 113 -116.
  • 8KeUey B. Industrialization tff mAb production technology: the bioprocessing industry at a crossroads[J]. MAbs, 2009, 1(5) : 443 -452.
  • 9Yokoyama WM, Christensen M, Santos GD, et al. Production of monoclonal antibodies [ J/OL ]. Curr Protoc Immunol, 2006, Chapter2: Unit 2.5. doi: 10. 1002/0471142735. im0205s74.
  • 10Friguet B, Chaffotte AF, Djavadi-Ohaniance L, et al. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay [ J ]. J Immunol Methods, 1985, 77(2) : 305 -319.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部